Literature DB >> 29339537

STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.

Uksha Saini1, Adrian A Suarez2, Shan Naidu1, John J Wallbillich3, Kristin Bixel1, Ross A Wanner1, Jason Bice4, Raleigh D Kladney4, Jenny Lester5, Beth Y Karlan5, Paul J Goodfellow1, David E Cohn1, Karuppaiyah Selvendiran6.   

Abstract

The initial molecular events that lead to malignant transformation of the fimbria of the fallopian tube (FT) through high-grade serous ovarian carcinoma (HGSC) remain poorly understood. In this study, we report that increased expression of signal transducer and activator of transcription 3 (pSTAT3 Tyr705) and suppression or loss of protein inhibitor of activated STAT3 (PIAS3) in FT likely drive HGSC. We evaluated human tissues-benign normal FT, tubal-peritoneal junction (TPJ), p53 signature FT tissue, tubal intraepithelial lesion in transition (TILT), serous tubal intraepithelial carcinoma (STIC) without ovarian cancer, and HGSC for expression of STAT3/PIAS3 (compared with their known TP53 signature) and their target proliferation genes. We observed constitutive activation of STAT3 and low levels or loss of PIAS3 in the TPJ, p53 signature, TILT, and STIC through advanced stage IV (HGSC) tissues. Elevated expression of pSTAT3 Tyr705 and decreased levels of PIAS3 appeared as early as TPJ and the trend continued until very advanced stage HGSC (compared with high PIAS3 and low pSTAT3 expression in normal benign FT). Exogenous expression of STAT3 in FT cells mediated translocation of pSTAT3 and c-Myc into the nucleus. In vivo experiments demonstrated that overexpression of STAT3 in FT secretory epithelial cells promoted tumor progression and metastasis, mimicking the clinical disease observed in patients with HGSC. Thus, we conclude that the STAT3 pathway plays a role in the development and progression of HGSC from its earliest premalignant states.Significance: Concomitant gain of pSTAT3 Tyr705 and loss of PIAS3 appear critical for initiation and development of high-grade serous carcinoma. Cancer Res; 78(7); 1739-50. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29339537      PMCID: PMC5907493          DOI: 10.1158/0008-5472.CAN-17-1671

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Protein inhibitor of activated STAT3 expression in lung cancer.

Authors:  Amy Kluge; Snehal Dabir; Ilse Vlassenbroeck; Rosana Eisenberg; Afshin Dowlati
Journal:  Mol Oncol       Date:  2011-03-30       Impact factor: 6.603

2.  Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.

Authors:  Mark A Eckert; Shawn Pan; Kyle M Hernandez; Rachel M Loth; Jorge Andrade; Samuel L Volchenboum; Pieter Faber; Anthony Montag; Ricardo Lastra; Marcus E Peter; S Diane Yamada; Ernst Lengyel
Journal:  Cancer Discov       Date:  2016-10-07       Impact factor: 39.397

3.  Correlative analyses of the expression levels of PIAS3, p-SHP2, SOCS1 and SOCS3 with STAT3 activation in human astrocytomas.

Authors:  Li-Hong Liu; Hong Li; Xiao-Xin Cheng; Qing-You Kong; Xiao-Yan Chen; Mo-Li Wu; Yan Li; Jia Liu; Cong Li
Journal:  Mol Med Rep       Date:  2016-12-28       Impact factor: 2.952

4.  HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.

Authors:  Karuppaiyah Selvendiran; Shabnam Ahmed; Alex Dayton; Yazhini Ravi; M Lakshmi Kuppusamy; Anna Bratasz; Brian K Rivera; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy
Journal:  Mol Cancer Res       Date:  2010-08-16       Impact factor: 5.852

Review 5.  Origin of ovarian cancer: molecular profiling.

Authors:  Dilip Kumar Dutta; Indranil Dutta
Journal:  J Obstet Gynaecol India       Date:  2013-06-21

6.  Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression.

Authors:  Emily C Brantley; L Burton Nabors; G Yancey Gillespie; Youn-Hee Choi; Cheryl Ann Palmer; Keith Harrison; Kevin Roarty; Etty N Benveniste
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

7.  Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Authors:  Alison M Karst; Paul M Jones; Natalie Vena; Azra H Ligon; Joyce F Liu; Michelle S Hirsch; Dariush Etemadmoghadam; David D L Bowtell; Ronny Drapkin
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

8.  Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein.

Authors:  Maria Sundvall; Anna Korhonen; Katri Vaparanta; Julius Anckar; Kalle Halkilahti; Zaidoun Salah; Rami I Aqeilan; Jorma J Palvimo; Lea Sistonen; Klaus Elenius
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

9.  FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis.

Authors:  K Levanon; S Sapoznik; K Bahar-Shany; H Brand; R Shapira-Frommer; J Korach; M S Hirsch; M H Roh; A Miron; J F Liu; N Vena; A H Ligon; S Fotheringham; D Bailey; R J Flavin; M J Birrer; R I Drapkin
Journal:  Oncogene       Date:  2013-09-30       Impact factor: 9.867

10.  High grade serous ovarian carcinomas originate in the fallopian tube.

Authors:  S Intidhar Labidi-Galy; Eniko Papp; Dorothy Hallberg; Noushin Niknafs; Vilmos Adleff; Michael Noe; Rohit Bhattacharya; Marian Novak; Siân Jones; Jillian Phallen; Carolyn A Hruban; Michelle S Hirsch; Douglas I Lin; Lauren Schwartz; Cecile L Maire; Jean-Christophe Tille; Michaela Bowden; Ayse Ayhan; Laura D Wood; Robert B Scharpf; Robert Kurman; Tian-Li Wang; Ie-Ming Shih; Rachel Karchin; Ronny Drapkin; Victor E Velculescu
Journal:  Nat Commun       Date:  2017-10-23       Impact factor: 14.919

View more
  10 in total

1.  Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.

Authors:  Helen E Burston; Oliver A Kent; Laudine Communal; Molly L Udaskin; Ren X Sun; Kevin R Brown; Euihye Jung; Kyle E Francis; Jose La Rose; Joshua Lowitz; Ronny Drapkin; Anne-Marie Mes-Masson; Robert Rottapel
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

2.  Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis.

Authors:  Deepika Neelakantan; Samrita Dogra; Bharat Devapatla; Pharavee Jaiprasart; Marie Claire Mukashyaka; Ralf Janknecht; Shailendra Kumar Dhar Dwivedi; Resham Bhattacharya; Sanam Husain; Kai Ding; Sukyung Woo
Journal:  Mol Cancer Res       Date:  2019-03-11       Impact factor: 5.852

3.  A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer.

Authors:  Kalpana Deepa Priya Dorayappan; Miranda L Gardner; Colin L Hisey; Roman A Zingarelli; Brentley Q Smith; Michelle D S Lightfoot; Rajan Gogna; Meghan M Flannery; John Hays; Derek J Hansford; Michael A Freitas; Lianbo Yu; David E Cohn; Karuppaiyah Selvendiran
Journal:  Cancer Res       Date:  2019-05-16       Impact factor: 12.701

4.  Multispectral Staining and Analysis of Extracellular Matrix.

Authors:  Carine M Renner; Mike R Visetsouk; Pamela K Kreeger; Kristyn S Masters
Journal:  Methods Mol Biol       Date:  2022

5.  Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.

Authors:  Orlandric Miree; Sanjeev Kumar Srivastava; Santanu Dasgupta; Seema Singh; Rodney Rocconi; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.

Authors:  Dmitriy W Gutkin; Michael R Shurin; Mounia Alaoui El Azher; Galina V Shurin; Liudmila Velikokhatnaya; Denise Prosser; Namhee Shin; Francesmary Modugno; Paul Stemmer; Esther Elishaev; Anna Lokshin
Journal:  Cancer Biomark       Date:  2019       Impact factor: 4.388

7.  Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.

Authors:  Eric J Norris; Qing Zhang; Wendell D Jones; Darla DeStephanis; Ashley P Sutker; Chad A Livasy; Ram N Ganapathi; David L Tait; Mahrukh K Ganapathi
Journal:  J Pathol       Date:  2019-05-14       Impact factor: 7.996

Review 8.  Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer.

Authors:  Sandra Muñoz-Galván; Amancio Carnero
Journal:  Cells       Date:  2020-06-04       Impact factor: 6.600

Review 9.  Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?

Authors:  Lynn Roy; Karen D Cowden Dahl
Journal:  Cancers (Basel)       Date:  2018-07-24       Impact factor: 6.639

Review 10.  Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition.

Authors:  Wook Jin
Journal:  Cells       Date:  2020-01-15       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.